Core Insights - The company has announced multiple clinical and preclinical advancements for three products (Nailike®, Lishengtuo®, APG-5918) selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting, with one receiving an oral presentation [1] - The company's original first-in-class drug, Orebatinib (Nailike®), has been selected for the ASH meeting for the eighth consecutive year, highlighting its ongoing clinical progress [1] - The original first-in-class drug, Lishatoclax (Lishengtuo®; R&D code: APG-2575), has two clinical advancements selected for the ASH meeting, marking its fourth consecutive year of selection [1] Product Developments - Nailike® is the first third-generation BCR-ABL inhibitor approved in China, with commercialization jointly managed by the company and Innovent Biologics. The company will present the latest data from the global Phase III POLARIS-1 study on Nailike® combined with low-intensity chemotherapy for newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients at the ASH meeting [2] - The company will also update data from a randomized controlled Phase II study on Nailike® for patients with tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia in chronic phase (CML-CP) and data for second-line treatment of non-T315I mutation CML-CP patients [2] - Lishatoclax is a novel oral Bcl-2 selective inhibitor developed by the company, approved in China for adult chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have undergone at least one systemic treatment including a Bruton tyrosine kinase (BTK) inhibitor. The company will present the latest advancements from a registered Phase II clinical study on Lishatoclax for relapsed/refractory (R/R) CLL/SLL patients [2] Event Information - The 67th ASH Annual Meeting is one of the largest international academic events in the field of hematology, covering research on the etiology and treatment of blood diseases. The event will take place from December 6 to December 9, 2025, in Orlando, Florida, in a hybrid format [3]
亚盛医药-B(06855)耐立克、利生妥、APG-5918的多项临床进展将在2025年美国血液学会年会(ASH)展示，其中一项获口头报告